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CRISPR/Cas9 technology enables the rapid generation of loss-of-function mu-
tations in a targeted gene in mammalian cells. A single cell harboring those
mutations can be used to establish a new cell line, thereby creating a CRISPR-
induced knockout clone. These clonal cell lines serve as crucial tools for ex-
ploring protein function, analyzing the consequences of gene loss, and investi-
gating the specificity of biological reagents. However, the successful derivation
of knockout clones can be technically challenging and may be complicated
by multiple factors, including incomplete target ablation and interclonal het-
erogeneity. Here, we describe optimized protocols and plasmids for generating
clonal knockouts in mammalian cell lines. We provide strategies for guide RNA
design, CRISPR delivery, and knockout validation that facilitate the derivation
of true knockout clones and are amenable to multiplexed gene targeting. These
protocols will be broadly useful for researchers seeking to apply CRISPR to
study gene function in mammalian cells. C© 2019 The Authors.
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INTRODUCTION
The CRISPR system initially evolved as a nucleic acid–targeting bacterial defense mech-
anism capable of conferring resistance to viral infection (Barrangou et al., 2007). It
has since been co-opted by scientists as a means to generate sequence-specific double-
strand breaks (DSBs) and to induce other precise alterations in the genomes of cells
and organisms (Cong et al., 2013). CRISPR has been particularly useful in the study
of mammalian genetics and cell biology, as mammalian somatic cells have historically
proven to be highly refractory to genetic modification (Komor, Badran, & Liu, 2017).
By expressing the Cas9 nuclease and a suitable guide RNA (gRNA) in mammalian
cells, a double-strand break can be introduced at a locus of interest. The cell then has
multiple options for repairing that break. If a suitable template is provided, the cell
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can use homology-directed repair to integrate a novel allele or transgene at the targeted
site (Ceasar, Rajan, Prykhozhij, Berman, & Ignacimuthu, 2016). Alternately, the cell
can repair the lesion via nonhomologous end joining (NHEJ), an error-prone process
that commonly results in an insertion or deletion (indel) mutation at the DSB location
(Brinkman et al., 2018). In this way, CRISPR can be used to introduce stable, nonre-
vertible alterations to mammalian genes. Below, we describe an efficient method to use
CRISPR to generate knockout clones in mammalian somatic cell lines. The protocol is
divided into five sections, as outlined in Figure 1:
1. Choosing a knockout strategy;
2. Selecting gRNA target sites and performing vector cloning;
3. Introducing gRNAs by transfection or transduction;
4. Isolation and expansion of single-cell clones;
5. Knockout verification by western blot analysis, PCR, and/or Sanger sequencing.
STRATEGIC PLANNING
Choosing a Knockout Strategy
To knock out a gene of interest, the nuclease Cas9 and a target-specifying guide RNA
must be delivered to the cell. Various CRISPR platforms are suitable for generating
knockouts, including “all-in-one” or one-plasmid system (in which Cas9 and the guide
RNA are encoded on the same vector), two-plasmid systems (in which Cas9 and the
guide RNA are encoded on different vectors), and direct ribonucleoprotein delivery.
Ribonucleoprotein assembly and delivery have been described elsewhere (Farboud et al.,
2018), and this protocol will focus on plasmid-based knockout strategies.
The efficiency of each CRISPR system is limited by the efficacy with which it can be
introduced into and expressed in the target cell. In the two-vector approach, a Cas9-
expressing plasmid is first stably transduced using lentiviruses into the target cell line.
Following selection for Cas9 expression, this line can be easily used to generate mul-
tiple knockout clones by expressing different guide RNAs. However, constitutive Cas9
expression may lead to higher levels of off-target mutagenesis, and some cell lines have
a tendency to silence virally expressed proteins (Ellis, 2005). In the one-vector approach,
the single Cas9/gRNA plasmid can be introduced into cells via either transfection or
transduction. However, the size of the provirus generated from the all-in-one vector is
near the lentiviral packaging limit, which may decrease subsequent viral titers (Kumar,
Keller, Makalou, & Sutton, 2001). In general, if a researcher is seeking to analyze dif-
ferent knockouts in the same cell line, we recommend using the two-vector approach
and generating a stable Cas9-expressing cell line. If a researcher is seeking to analyze
a single knockout and to minimize off-target effects, then transient transfection of the
all-in-one vector may be superior. A number of labs have developed CRISPR plasmids
with convenient drug-resistance and fluorescent markers. In this protocol, we describe
the use of plasmids that have been generated and validated by our own laboratory and
by the Vakoc laboratory at Cold Spring Harbor Laboratory, though many of the other
CRISPR vectors available from Addgene could be used in their place.
The Cas9 variant used in this protocol was obtained from the bacteria Streptococcus
pyogenes and cuts 3 base pairs (bp) upstream of the prospacer adjacent motif (PAM)
sequence, NGG. A number of tools to identify potent guide RNA sequences have been
described (Graham & Root, 2015). In general, targeting Cas9 to exons that encode
functional protein domains is more likely to ablate gene function than simply targeting
a 5′ exon (Shi et al., 2015). Exon-targeting guide RNA sequences can be identified
using GUIDES (http://guides.sanjanalab.org/) (Meier, Zhang, & Sanjana, 2017). We
also frequently design guide RNAs using Benchling (http://www.benchling.com/), which
offers an easy-to-use graphical user interface for CRISPR experiments. Benchling doesGiuliano et al.
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Figure 1 Schematic outline of the knockout process. The procedure includes (1) choosing a
knockout strategy; (2) selecting gRNA target sites and performing vector cloning (Support Pro-
tocols 1–3, Basic Protocol 1); (3) introducing CRISPR plasmids by transfection or transduction
(Basic Protocols 2–5); (4) isolation and expansion of single-cell clones (Basic Protocol 6, Alternate
Protocol 1); and (5) knockout verification by western blot analysis, PCR, and/or Sanger sequencing
(Support Protocol 4, Basic Protocols 7–9).
not currently support domain annotations, but these can be obtained by cross-referencing
guides found on Benchling with Ensembl or any other genome database. We often design
three to five guides per target gene as some gRNA sequences may be more efficient than
others; however, with the methods described in this protocol, we have found most gRNAs
capable of cutting the target locus sufficiently well. Giuliano et al.
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The number of gRNAs introduced into cell lines will vary depending on the experimental
goals of the project and any unique characteristics of the gene of interest. The use of
one gRNA is frequently sufficient to knock out the target gene within a portion of cells
in a population (Popp & Maquat, 2016). However, as described in the Commentary
below, alternative splicing, downstream translational initiation, and the production of
functional protein fragments may occasionally allow cells to bypass single Cas9-induced
lesions (Lalonde et al., 2017; Sharpe & Cooper, 2017). To maximize the likelihood of
knocking out a target gene, a two-guide strategy can be employed. In this approach, two
gRNAs, targeting two distinct exons, are introduced into the cells. This double cut can be
repaired through either the generation of two independent mutations or the elimination
of the DNA between the two targeted sites. It is important to note that the introduction
of multiple guide RNAs into a cell may result in an increase in off-target mutagenesis.
Thus, it remains crucial to validate knockout phenotypes by using different combinations
of guide RNAs and by analyzing multiple independent clones by western blotting, PCR,
and sequencing.
Additionally, when generating KO cell lines, it is often useful to have control cell lines for
downstream experimental comparisons. For this purpose, we often generate single-cell-
derived clonal lines from cells harboring gRNAs targeting the safe harbor loci Rosa26
or AAVS1.
Guide RNA Cloning
To begin with, gRNAs targeting the gene of interest must first be cloned into the gRNA
expression vector of choice.
SUPPORT
PROTOCOL 1
ISOLATION OF PLASMID DNA
In order to clone in gRNA sequences in later steps of the protocol (Basic Protocol 1), it
is necessary to first purify sufficient quantities of the gRNA plasmid backbone (Table 1).
These plasmid backbones can be obtained from Addgene.
Materials
Plasmid(s) of interest (Addgene)
Appropriate Escherichia coli strain
LB + 100 µg/ml ampicillin medium
50% (v/v) glycerol
Table 1 CRISPR Plasmids
Plasmid(s) Addgene no. Purpose
One-plasmid knockout systems
Lenti-Cas9-gRNA-GFP 124770 Coexpress Cas9, a gRNA, and GFP
Lenti-Cas9-gRNA-TagBFP2 124774 Coexpress Cas9, a gRNA, and TagBFP2
Two-plasmid knockout systems
LentiV_Cas9_puro 108100 Expresses Cas9 with puromycin resistance
LRG2.1 108098 Expresses a gRNA with GFP
LRCherry2.1 108099 Expresses a gRNA with mCherry
Lenti_sgRNA_EFS_BFP 120577 Expresses a gRNA with eBFP
LRG2.1-mOrange 124772 Expresses a gRNA with mOrange
LRG2.1-CyOFP1 124771 Expresses a gRNA with CyOFP1
LRG2.1-TagBFP2 124773 Expresses a gRNA with TagBFP2Giuliano et al.
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GeneJET Plasmid Maxiprep Kit (Thermo Fisher Scientific; cat. no. K0491)
NanoDrop spectrophotometer or equivalent
1.5-ml freezing tubes
1.5-ml microcentrifuge tubes
1. Obtain the desired plasmid(s) from Addgene.
2. After receiving the stab culture of E. coli, inoculate the bacteria in 2 ml of LB +
100 µg/ml ampicillin medium overnight at 37°C.
3. The next day, prepare glycerol stocks by resuspending 500 µl of the bacterial culture
in 500 µl of 50% glycerol and store at in 1.5-ml freezing tubes −80°C. Additionally,
transfer 1 ml of the overnight culture into 250 ml of LB + 100 µg/ml ampicillin
medium and allow to grow for an additional 12-18 hr at 37°C.
4. Isolate the plasmids from the E. coli stock using the GeneJET Plasmid Maxiprep
Kit according to the manufacturer’s instructions. Quantify the DNA concentration
and purity using a NanoDrop spectrophotometer and store aliquots of the plasmid-
bearing stock in 1.5-ml microcentrifuge tubes at −20°C for later use.
SUPPORT
PROTOCOL 2
PREPARATION OF COMPETENT STBL3 E. COLI FOR gRNA CLONING
The repetitive sequences in the lentiviral CRISPR plasmids may be unstable when the
plasmids are propagated in E. coli. We therefore recommend transforming the cloned
plasmids constructed in Basic Protocol 1 into the recombination-deficient Stbl3 strain of
E. coli to maximize vector stability (Al-Allaf, Tolmachov, Zambetti, Tchetchelnitski, &
Mehmet, 2013). Although purchasing premade competent Stbl3 is very expensive, we
generate our own batches of competent Stbl3 cells using the Zymo Research Mix & Go
Transformation Kit.
Materials
One ShotTM Stbl3TM Chemically Competent E. coli (Invitrogen; cat. no. C737303)
Mix & Go E. coli Transformation Kit and Buffer Set (Zymo Research; cat. no.
T3001)
1. Prepare fresh batches of competent Stbl3 E. coli by following the Mix & Go Kit’s
instructions.
2. Store aliquots of cells at −80°C for later use.
SUPPORT
PROTOCOL 3
OBTAINING GUIDE RNA OLIGONUCLEOTIDES
Guide RNAs are cloned into expression vectors by BsmBI digestion. After a suitable
20-bp guide RNA sequence is identified, BsmBI restriction sequences should be added
to each strand of the gRNA sequence, as shown here:
Guide RNA post-annealing schematic:
Forward oligo: 5′-CACCG–20-bp gRNA sequence-3′
Reverse oligo: 3′-C–20-bp gRNA sequence–CAAA-5′
Guide RNA oligo 5′-3′ sequences:
Forward oligo: 5′-CACCG–20 bp gRNA sequence-3′
Reverse oligo: 5′-AAAC–20 bp gRNA sequence–C-3′
“CACCG” and “AAAC” are added to the oligos to ensure compatibility for cloning using
a BsmBI digestion. The single C at the 3′ end of the reverse oligo is needed to anneal the Giuliano et al.
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sequence to the additional G added to the forward oligo. Guide RNAs are generally 25
bp long after these modifications are added to the sgRNA sequence.
Synthetic oligos of the designed guides can be purchased commercially from Integrated
DNA Technologies (IDT; https://www.idtdna.com) or any commercial source. Generally,
25 nmol of DNA oligos from IDT prepared with standard desalting provides more
than enough material for gRNA cloning (see Strategic Planning for guidelines for gRNA
design). Although we have provided a list of gRNA-expressing vectors that we commonly
use in Table 1, a number of other gRNA vectors can be found on Addgene, and these




The gRNA oligos can be cloned into either the gRNA vector (two-vector system) or
the “all-in-one” vector (one-vector system) by restriction digestion and ligation. If the
two-gRNA approach is chosen, each gRNA can be cloned into a vector with different
fluorescent markers to allow downstream sorting of cells that harbor both gRNAs. The
gRNA cloning protocol consists of five overall steps: (1) linearization of the plasmid
backbone, (2) 5′ phosphorylation and annealing of the oligonucleotides, (3) ligation of
the annealed oligonucleotides into the linearized vector, (4) transformation of the ligation
product into Stbl3 cells, and (5) sequence verification of the gRNA.
Materials
gRNA plasmid backbone or all-in-one vector (Support Protocol 1)
Competent Stbl3 cells (Support Protocol 2)
BsmBI restriction endonuclease and NEB buffer 3.1 (NEB; cat. no. R0580)
Nuclease-free distilled, deionized water (ddH2O)
Alkaline phosphatase, calf intestinal (CIP) stock (10,000 U/ml; NEB; cat. no.
M0290)
NucleoSpin R© Gel and PCR clean-up (Macherey-Nagel; cat. no. 740609.50)
100 µM gRNA oligos (IDT or other DNA synthesis manufacturer; see Strategic
Planning and Support Protocol 3)
T4 polynucleotide kinase (NEB; cat. no. M0201)
T4 DNA ligase and appropriate buffer (NEB; cat. no. M0202)
LB + 100 µg/ml ampicillin culture plates
LB + 100 µg/ml ampicillin medium
50% (v/v) glycerol
QIAprep Spin Miniprep Kit (Qiagen; cat. no. 27106)




DNA NanoDrop spectrophotometer or equivalent
0.2-ml thin-walled PCR tubes
Thermocycler
1.5-ml freezing tubes
Additional reagents and equipment for agarose gel electrophoresis (Current
Protocols article: Voytas, 2001)
1. To linearize the guide RNA plasmid backbone, mix the following in a 1.5-ml mi-
crocentrifuge tube:
8 µg gRNA backbone
2 µl BsmBI enzymeGiuliano et al.
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5 µl NEB buffer 3.1
Nuclease-free ddH2O to 50 µl final.
Incubate for 3 hr at 55°C.
2. After 3 hr of digestion, add 1 µl 10,000 U/ml CIP stock solution to each reaction
and incubate 1 hr more at 37°C.
3. Run the digestion mixture on a 1% agarose gel. Two bands should be observed
(bands around 11 and 2 kb for the all-in-one vector and bands around 7.5 and 2 kb
for the vector backbone of the two-plasmid system). Using the NucleoSpin R© Gel
and PCR Clean-up Kit, cut out and extract the larger band. Determine the DNA
concentration of the extracted vector using a NanoDrop spectrophotometer, and
store the linearized vector at −20°C.
4. To anneal and phosphorylate the 5′ end of the gRNA-containing oligos, set up the
following reaction in a 0.2-ml PCR tube:
1 µl forward oligo (100 µM)
1 µl reverse oligo (100 µM)
1 µl 10× T4 ligase buffer
6.5 µl nuclease-free ddH2O
0.5 µl T4 PNK enzyme.




5 s 80°C (ramp 0.1°C/s)
30 s 70°C (ramp 0.1°C/s)
30 s 60°C (ramp 0.1°C/s)
1 min 50°C (ramp 0.1°C/s)
2 min 40°C (ramp 0.1°C/s)
2 min 30°C (ramp 0.1°C/s)
Hold at 4°C.
6. After the PCR program is completed, dilute the reaction 1:200 with nuclease-free
ddH2O and store at −20°C.
7. To ligate the sgRNA into the linearized guide RNA backbone, set up the following
reaction and incubate 30 min at room temperature. A reaction excluding the gRNA
oligos from step 6 should be included the first time a new batch of digested vector
is used to confirm the efficiency of the digestion. No colonies above background
levels should be seen on Stbl3 cells transformed with only digested vector.
X µl (25 ng) digested vector from step 3
Y µl ddH2O to 10 µl total volume
1 µl phosphorylated and annealed oligo duplex from step 6
1 µl 10× T4 ligase buffer
1 µl T4 ligase.
8. To transform the sgRNA vectors into Stbl3 E. coli cells, add 5 µl of the ligation
reaction from step 7 to 50 µl Stbl3 cells. Allow the mixture to rest on ice for 5 min.
9. Plate appropriate dilutions of the Stbl3 E. coli cells on LB + 100 µg/ml ampicillin
plates and allow to grow overnight at 37°C.
Giuliano et al.
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10. Pick three to five colonies per gRNA and allow to grow in 3 ml LB + 100 µg/ml
ampicillin medium overnight at 37°C.
11. After overnight growth, make 1 ml glycerol stocks of each of the colonies by mixing
the LB culture 1:1 with 50% glycerol and storing at −80°C.
12. To verify the sequence of the sgRNA plasmid, generate a glycerol stock (see Sup-
port Protocol 1, step 3), purify the vectors from the bacteria in the liquid culture
using the QIAprep Spin Miniprep Kit, and sequence the plasmids with the U6
primer.
The U6 primer will initiate sequencing at the promoter region upstream of the location
where the sgRNA should be inserted.
CRISPR Delivery
The CRISPR system described in this protocol can be introduced into the cells of interest
in a number of ways, including:
 Transfection of the all-in-one CRISPR plasmid (Basic Protocol 5);
 Transfection of a gRNA plasmid into a Cas9-expressing cell line (cell line generation:
Basic Protocols 2 and 3; transfection: Basic Protocol 5);
 Transduction of the all-in-one CRISPR plasmid (Basic Protocol 2 and 4);
 Transduction of a gRNA plasmid into a Cas9-expressing cell line (cell line generation:
Basic Protocols 2 and 3; transduction: Basic Protocol 2 and 4).
In general, transient expression of the CRISPR components may lead to fewer off-target
effects while also decreasing on-target efficiency. Suitable strategies will depend on the
researchers’ particular experimental goals and the system(s) in which they are working.
Below, we describe various protocols for transfection and transduction to introduce the
CRISPR plasmids into the cells of interest.
BASIC
PROTOCOL 2
CALCIUM PHOSPHATE TRANSFECTION TO PRODUCE LENTIVIRUS
All lentiviruses used in this protocol (viral particles containing plasmids that express
Cas9, a guide RNA, or the all-in-one vector) are generated in HEK293T cells via calcium
phosphate transfection (Chang, Marran, Valentine, & Hannon, 2013). This transfection
protocol involves the use of two viral packaging plasmids (PsPAX2.0 and VSVG). If
the two-vector approach is used, separate lentiviral pools should be generated for each
vector.
Materials
HEK293T cells (ATCC CRL-3216)
CRISPR plasmid DNA (“all-in-one” plasmid or gRNA/Cas9 plasmids from Basic
Protocol 1)
psPAX2.0 plasmid (Addgene plasmid no. 12260)
VSVG plasmid (Addgene plasmid no. 98286)
2 M CaCl2
Solution B (2× HEPES-buffered saline; see recipe).
100 mM chloroquine (Cayman Chemical; cat. no. 14194)
DMEM medium supplemented with 10% FBS, 1% Pen/Strep, and glutamine (Life
Technologies; cat. no. 11995-073)
10-cm tissue culture plates with preferred culture medium for DMEM/10% FBS
with 1% Pen/Strep and glutamine HEK293T cells
5-ml polystyrene tubes
0.45-µM filterGiuliano et al.
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1. Prior to transduction, split HEK293T onto a 10-cm plate to obtain cells that are
70-80% confluent at the time of transfection.
2. In one tube, prepare solution A (total volume 500 µl) by adding, in the following
order:
a. 20 µg CRISPR plasmid DNA
b. 25 µg psPAX2.0 plasmid
c. 4 µg VSVG plasmid
d. ddH2O as required for a 500 µl total volume
e. 62.5 µl 2 M CaCl2
3. Pipet 500 µl solution B into a separate tube.
4. Use a pipet to blow bubbles into solution B while adding solution A to solution B
dropwise.
Bubbles will aid the even formation of precipitants, which is a crucial step in determining
the success of a transfection.
5. Incubate this mixture 15 min room temperature.
6. During the incubation, add 2.5 µl 100 mM chloroquine to the 10-cm plate of
HEK293T cells from step 1.
7. After the 15-min incubation is done, add the transfection mixture dropwise around
the 10-cm plate and then return the plate to a tissue culture incubator at 37°C.
8. At 8-14 hr after transfection, replace the medium on the HEK293T cells with fresh
10% FBS DMEM medium.
9. Start collecting virus 24 hr after transfection. To harvest virus, collect all the old
medium on the HEK293T cells using a syringe. Separate cell debris from viral
supernatant using a 0.45-µM filter, and either store the supernatant at −80°C or add
it to a recipient cell line immediately. Typically, virus can be collected three times
within the 24- to 72-hr window after transfection. To perform multiple harvests, add
an equal volume of the medium back to the cells and repeat the collection protocol
the next day. The protocol can also be scaled up (to 15-cm plates) or down (to 6- or
12-well plates) as needed.
Several of the CRISPR plasmids described in this protocol contain a fluorescent marker
and can be easily titered. To determine viral titer, add increasing volumes of virus to a
recipient cell line using the transduction protocol listed below. Three days after trans-
duction, quantify the fraction of fluorescent cells for each volume of virus to determine
the number of infectious particles per microliter of solution. However, titration is often
unnecessary, as the above transfection protocol is highly efficient. If titration is required




GENERATING A CAS9-EXPRESSING CELL LINE
When using the two-vector system, a stable cell line that expresses Cas9 must first be gen-
erated. The cell line can then be reused in multiple knockout experiments. Alternatively,
a number of vendors offer Cas9-expressing cell lines, some of which have inducible Cas9
expression (https://www.genecopoeia.com).
Materials
Cas9 lentiviral supernatant from lentivirus generated using the calcium phosphate
transfection protocol (Basic Protocol 2)
Recipient mammalian cell line Giuliano et al.
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Polybrene (Santa Cruz Biotechnology; cat. no. sc-134220)
Appropriate selective agent for the plasmid used
Additional reagents and equipment for cell culture and trypsinization (Current
Protocols article: Phelan, 1996)
1. Trypsinize the target cells and plate them so that they will be 50% confluent.
2. Mix supernatant from the lentiviral culture into cells 1:1: e.g., add 5 ml viral super-
natant to 5 ml cell culture.
3. Add polybrene to 8 µg/ml final.
4. Change medium 24 hr after transduction.
5. At 48 hr after transduction, select for Cas9 expression.
The Cas9 lentiviral plasmid most commonly used in our lab (Addgene plasmid no.
108100) harbors a puromycin-resistance marker, and we select for Cas9-expressing cells
using 1-4 µg/ml puromycin (Thermo Fisher Scientific; cat. no. A11138-03). In some cell
lines, sufficient Cas9 expression can be generated by a single round of transduction
followed by 3-5 days of selection. In other cell lines (particularly those that silence viral
transgenes), optimal Cas9 expression requires multiple rounds of lentiviral transduction
followed by 1-2 weeks of drug selection. Cas9 expression can be checked in the population




TRANSDUCING GUIDE RNAs OR ALL-IN-ONE VECTOR INTO RECIPIENT
CELLS
Guide RNA or all-in-one vectors can be permanently introduced into a recipient cell line
by the transduction protocol described below.
Materials
Recipient mammalian cell line (use cell line from Basic Protocol 3 for two-vector
system)
Supernatant with lentiviruses carrying cloned gRNA vector or all-in-one vector
(Basic Protocol 2)
Polybrene (Santa Cruz Biotechnology; cat. no. sc-134220)
6-well culture plates
Additional reagents and equipment for cell culture and trypsinization (Current
Protocols article: Phelan, 1996)
1. Trypsinize the target cells and plate them in 6-well plates so that they will be50%
confluent.
Typically, plating one well more than the number of transduction reaction is sufficient.
The extra well can be used as an untransduced control when monitoring transduction
efficiency.
2. Mix lentiviral supernatant into culture medium in 1:1 (or using an appropriate
amount determined by titration).
3. Add polybrene to 8 µg/ml final.
4. Change medium 24 hr after transduction.
5. Monitor transduction efficiency based on the fluorescent marker present on the
gRNA or all-in-one vector using a fluorescence microscope.
Giuliano et al.
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BASIC
PROTOCOL 5
TRANSFECTING GUIDE RNAs OR THE ALL-IN-ONE VECTOR INTO
RECIPIENT CELLS
Guide RNAs or all-in-one vectors can be temporarily introduced into a recipient cell
line by a variety of transfection methods. We have found that transfection efficiency can
vary greatly for different methods with different recipient cell lines. In general, we find
that Lipofectamine 3000 is most likely to produce the highest transfection rates with
the least amount of optimization required. However, in specific circumstances, other
reagents (Lipofectamine 2000, TransIT-LT1, etc.) may yield superior results. In general,
we recommend starting with Lipofectamine 3000 and then testing other reagents if
necessary.
To introduce CRISPR plasmids with Lipofectamine 3000, we use the following protocol
(slightly modified from the manufacturer’s protocol).
Materials
Recipient mammalian cell line (use the cell line from Basic Protocol 3 for the
two-vector system)
Lipofectamine 3000 (Thermo Fisher Scientific; cat. no. L3000001)
P3000 Reagent (supplied with Lipofectamine 3000)
Opti-MEM Reduced Serum Media (Thermo Fisher Scientific; cat. no. 31985088)




6-well tissue culture plates
Fluorescence microscope
1. Plate the target cell line so that it will be 60-80% confluent in a 6-well plate the next
day.
2. Warm transfection reagents to room temperature.
3. Add 7.5 µl Lipofectamine 3000 reagent to 125 µl Opti-MEM medium (called “tube
A”).
4. Add 5 µg plasmid DNA (gRNA or all-in-one vector) and 10 µl P3000 Reagent to
125 µl medium (called “tube B”).
5. Mix the contents of tube A and tube B and incubate the mixture at room temperature
for 5 min.
6. Change the medium on the recipient plate to Pen/Strep-free medium.
7. Add the transfection mixture to the recipient cells dropwise.
8. Change the medium 24 hr after transfection.
9. Confirm transfection efficiency by assessing the fluorescent marker under a fluo-
rescence microscope. Although higher transfection efficiencies will allow for easier
knockout enrichment by FACS, even low transfection rates will allow you to proceed
with the protocol.
Clonal Expansion of Knockout Cell Lines
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BASIC
PROTOCOL 6
SINGLE-CELL EXPANSION BY DILUTION PLATING
After introduction of the gRNA(s) by transduction or transfection, single cells must be
isolated in order to generate clonal lines that can be verified as complete knockouts. Two
common methods for this are dilution cloning and fluorescence-activated cell sorting
(FACS) of single cells (Alternate Protocol 1). Although both approaches can yield single
cell–derived clones, FACS sorting is often more effective given its ability to specifically
isolate double-positive cells. However, dilution cloning is cheaper and may cause less
cellular stress than sorting.
Materials
Appropriate cell culture medium
Standard cell culture plates:
10-cm plates (VWR: cat. no. 25382-701)
96-well flat-bottom plates (VWR: cat. no. 29442-056)
Microscope
Additional reagents and equipment for cell culture and trypsinization (Current
Protocols article: Phelan, 1996)
1. Harvest the transduced cells by trypsinization.
2. Count the cells and dilute to a concentration of 20 cells per 100 µl.
3. Using a multichannel pipette, pipette 200 µl of the diluted cells into the first row of
a 96-well plate.
4. Pipette 100 µl of the appropriate culture medium into all remaining wells in the
plate.
5. Take 100 µl from the first row of the plate containing cells and mix it with the
100 µl of appropriate medium in the row below. This will result in a two-fold
dilution of the cell concentration for the second row.
6. Repeat this process down the rows of the plate, resulting in a series of two-fold
dilution down the rows. This will result in some proportion of the wells containing
a single cell.
7. Check by microscopy for wells that contain a single cell that are single or double-
positive for the gRNA marker(s). This can be done immediately following dilution
or 12-24 hr later, after the cells have settled. Circle these wells.
8. Wells with single cells should be expanded: allow the cells to grow to form micro-
colonies (50-100 cells). Split the microcolony into a fresh well of a 96-well plate.
Once that well is near confluence, split to a well of a 48-well plate. Continue ex-




SINGLE-CELL ISOLATION AND EXPANSION BY FACS
FACS can be used in multiple ways to isolate single cells. When using the two-gRNA
approach, FACS can be used to isolate cells that express both gRNAs by sorting for both
fluorescent markers. Depending on your choice of system and the setup in your FACS
facility, there are several approaches for this, listed below.
1. Double-positive single cells can be sorted directly by FACS and plated into 96-well
plates.
2. Bulk populations of double-positive cells can be isolated by FACS and plated into
96-well plates by dilution plating, as described in Basic Protocol 6.Giuliano et al.
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Figure 2 Two-guide knockout validation. (A) Schematic illustrating the domain structure of MELK and sites
targeted by guide RNAs. (B) Diagram showing the exons of MELK targeted by each gRNA. Half-arrows indicate
the deletion or cut-site primers used to verify the presence of recombination events. (C) Sample results from
PCR amplification verifying multi-exon deletions in three independent MELK knockout (MELK-KO) clones
transduced with two guide RNAs. (D) Sample results from Sanger sequencing of deletion PCR products from
three MELK-KO clones. Clones transduced with the g1/g3 and g1/g4 combinations have homozygous deletions
in MELK, whereas the clone transduced with the g2/g3 combination contain a heterozygous recombination
event. If necessary, the heterozygous alleles could be further analyzed using TOPO cloning. The highlighted
region in each chromatogram indicates the base pairs recognized by a guide RNA. (E and F) Sample results
from validation of MELK knockout through western blotting using two antibodies that bind to two different
epitopes. Clones transduced with guide RNAs targeting Rosa26, a nonessential and noncoding gene, were
used as a control. (Reprinted from Lin et al., 2017, with permission of eLife.)
3. Bulk populations of double positive cells can be isolated by FACS and plated on
10-cm plates at a low concentration to allow single cells to form colonies:
a. Plate 100-200 cells from the FACS-sorted sample of double-positive cells onto a
10-cm plate.
b. Use a microscope to identify isolated microcolonies that begin to grow.
c. Use cloning cylinders (Chemglass; cat. no. CLS-1777-02) to isolate and trypsinize
the individual microcolonies, and then move them to a 96-well or 48-well plate
for clonal expansion.
Clones can be expanded by plating to progressively larger plates until there are enough
cells to freeze and take DNA and protein lysates for knockout verification. Giuliano et al.
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Figure 3 One-guide knockout validation. (A) Schematic illustrating the domain structure of MELK and sites
targeted by guide RNAs. (B) Diagram showing the exons of MELK targeted by each gRNA. Half-arrows
represent cut-site primers used to verify the presence of indels. (C) Sample results from Sanger sequencing
of cut-site PCR products or single alleles isolated by TOPO cloning. MELK-KO c1 has heterozygous cut-
site mutations, whereas MELK-KO c2 has a homozygous mutation. Highlighted regions indicate base pairs
recognized by each guide RNA. (D and E) Sample results from validation of MELK knockout through western
blotting using two antibodies that bind to two different epitopes. Clones transduced with guide RNAs targeting
Rosa26, a nonessential and noncoding gene, were used as a control. (Reprinted from Giuliano et al., 2018,
with permission of eLife.)
Validation of Gene Knockout
The cornerstone of any strategy to verify that a protein of interest has been ablated is
demonstrating its absence by western blot analysis. However, single western blots may
be misleading, and characterizing the precise alterations caused by CRISPR at the DNA
level may provide additional useful information. The options for knockout validation
also differ slightly depending on whether the one-guide or two-guide approach was used.
In particular, if a gene was targeted by two independent guide RNAs, a PCR-based
screening strategy can be applied to rapidly assess the knockout status of dozens of
potential clones. Alternatively, the presence of indel mutations can be verified at each cut
site, though this becomes more challenging if the resultant mutations are heterozygous.
No single technique is perfect, and we recommend that researchers apply a combination
of the methods described below to characterize the CRISPR-induced lesions and identify
valid knockout clones. Figures 2 and 3 show representative results of different validationGiuliano et al.
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experiments to confirm knockout of the MELK kinase from cancer cell lines (Giuliano,
Lin, Smith, Palladino, & Sheltzer, 2018; Lin, Giuliano, Sayles, & Sheltzer, 2017).
SUPPORT
PROTOCOL 4
GENOMIC DNA EXTRACTION FROM POTENTIAL KNOCKOUT CELLS
To confirm gene knockout by PCR (Basic Protocol 7), mutation sequencing (Basic
Protocol 8), or TOPO cloning (Basic Protocol 9), genomic DNA must first be prepared
from control and potential knockout cell lines.
Materials
Potential knockout cells
DNeasy Blood & Tissue Kit (Qiagen; cat. no. 69506)
Cell culture materials
6-well tissue culture plates
15-ml tubes
1.5-ml microcentrifuge tube
NanoDrop spectrophotometer or equivalent
1. Plate300,000 cells in one well of a 6-well plate for each putative knockout clone.
If the number of clones need to be screen is large and plating 300,000 cells per clone
is not optimal, cells can be plated in smaller well plates and QuickExtract kits can be
employed instead of DNeasy kits. However, for high-quality genomic DNA and clean
sequencing results in later steps, we do recommend plating 300,000 cells.
2. The next day, follow the manufacturer’s protocol from the DNeasy Blood & Tissue
Kit to isolate the genomic DNA.
3. Quantify the concentration and purity of the DNA with a NanoDrop spectropho-
tometer. A DNA yield of 1 µg is ideal.
BASIC
PROTOCOL 7
GENOMIC DELETION AND CUT-SITE PCR
To screen for genomic knockouts, design two sets of PCR primers: one that spans the pu-
tative deletion and one that spans either cut site. The primers should recognize a sequence
that is 100-200 bp from the CRISPR cut site, as larger sequences are more difficult
to amplify. Suitable primers can be designed using NIH Primer Blast (https://www.ncbi.
nlm.nih.gov/tools/primer-blast/) and ordered from IDT (https://www.idtdna.com).
Materials
Genomic DNA (Support Protocol 4)
Primers
Taq 2× Master Mix (NEB; cat. no. M0270)
Nuclease-free distilled, deionized water (ddH2O)
Thermocycler
0.2-ml thin-walled PCR tubes
Additional reagents and equipment for agarose gel electrophoresis (Current
Protocols article: Voytas, 2001)
1. For each genomic DNA sample, set up one reaction with primers amplifying a single
cut site and another reaction with primers spanning the deletion. As controls, set up
a PCR reaction with genomic DNA from a wild-type population and a PCR reaction
with genomic DNA from a mixed population transduced/transfected with the two
guides. Follow the manufacturer’s instructions to perform PCR with the Taq 2×
Master Mix. Giuliano et al.
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2. After the PCR reactions are complete, run the PCR products on a 2% agarose gel.
If the DNA region between the cut sites was removed, then a PCR product would be
expected in the reactions with deletion primers and not in the reactions with the cut-site
primers. The presence of a reaction product in the cut-site primer lane indicates that not
all copies of the intervening genetic material have been excised.
BASIC
PROTOCOL 8
CHARACTERIZING CRISPR-INDUCED MUTATIONS BY SEQUENCING
If the researcher chooses the single-guide knockout approach, then demonstrating the
presence of an indel mutation at the guide RNA cut site is strong evidence that the
targeted gene has been knocked out. (Note that this approach is also appropriate if two
gRNAs are used but no full deletions are detected.) Cut-site analysis can be performed by
PCR-amplifying the region targeted by the guide RNA and then subjecting the amplicon
to Sanger sequencing. In the event that the lesion is found to be heterozygous, then TOPO
cloning can be applied to sequence individual alleles found within the clone.
For this approach, first isolate genomic DNA from each putative knockout clone and
design PCR primers to amplify a200- to 400-bp region around the cut site, as described
above. Then, perform PCR and sequence the amplicon:
Materials
Genomic DNA (Support Protocol 4)
Primers
2× Taq Master Mix (NEB; cat. no. M0270)




0.2-ml thin-walled PCR tubes
1.5-ml microcentrifuge tube
Additional reagents and equipment for agarose gel electrophoresis (Current
Protocols article: Voytas, 2001)
1. To set up a PCR reaction, follow the manufacturer’s protocol for PCR guidelines
and thermocycler settings for the 2× Taq master mix. As a control, set up a PCR
reaction using the genomic DNA from a wild-type population.
2. Run the PCR product on a 2% gel. Verify that a band of the correct size is present.
3. Using the NucleoSpin R© gel and PCR clean-up, isolate the PCR fragments from the
mixture.
4. Set up Sanger sequencing reactions according to the sequencing facility’s guidelines.
The forward and reverse primers used for PCR can also be applied for sequencing.
5. Compare sequences between the wild-type population and each clone using standard




CHARACTERIZING HETEROZYGOUS MUTATIONS BY TOPO CLONING
AND SEQUENCING
If Sanger sequencing reveals that the CRISPR-induced lesion is heterozygous (as evi-
denced by the presence of overlapping bases in the chromatogram; Figure 3C), the alleles
can be deconvolved by TOPO cloning and sequencing. First, the individual alleles areGiuliano et al.
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cloned into the TOPO vector and transformed into E. coli. Next, single colonies are
picked and the plasmids are reisolated by miniprep and then sequenced individually.
In this way, researchers can confirm the presence of indel mutations in each allele in a
targeted cell line.
Note that the Taq polymerase used for PCR in this protocol leaves an adenine overhang
at the 3′ end of the PCR product. As a result, the TOPO TA kit (Thermo Fisher Scientific;
cat. no. 450071), in which the vector contains a T overhang, should be used for TOPO
cloning of these amplicons. If a different polymerase with proofreading activity is used
for PCR, then the TOPO blunt-end kit (cat. no. 450159) should be used instead.
Materials
PCR products from cut-site PCR reactions (Basic Protocol 8)
TOPOTM TA CloningTM Kit for Sequencing, without competent cells (cat. no.
450071)
Competent Stbl3 E. coli cells (Support Protocol 2)
Nuclease-free water
LB + 50 µg/ml kanamycin culture plates
LB + 50 µg/ml kanamycin medium
QIAprep Spin Miniprep Kit (Qiagen; cat. no. 27106)
0.2-ml thin-walled PCR tubes
Thermocycler
1. Ligate the products from cut-site PCR into TOPO plasmids according to the manu-
facturer’s guidelines.
2. Add 2-3 µl of the ligation product to an aliquot of Stbl3 E. coli cells. Incubate the
cells on ice for 5 min and then plate the E. coli cells on LB + kanamycin plates.
Allow the plates to grow at 37°C overnight.
3. The next day, pick 15 colonies from the plates and grow each of them in 2 ml LB +
kanamycin medium.
4. Isolate the plasmids from the E. coli cells using the QIAprep Spin Miniprep Kit.
5. Set up Sanger sequencing reactions according to the sequencing facility’s guidelines.
The forward primer or M13 forward primer from the TOPO cloning kit can be used
to sequence the plasmids. Set up a sequencing reaction using the PCR product from
the wild-type population as well.
6. Analyze the resulting alleles using standard chromatogram analysis software. Indels
should be observed at or near the nuclease targeted site.
REAGENTS AND SOLUTIONS
Solution B (HEPES-buffered saline)
280 mM NaCl
1.5 mM anhydrous Na2HPO4
50 mM HEPES
12 mM dextrose or glucose
10 mM KCl
Dilute solution to 950 ml with ddH2O
Adjust pH to 7 with 1 M NaOH
Bring final volume up to 1 L with ddH2O
Adjust pH to 7 with 1 M NaOH
H2O to 1 liter Giuliano et al.
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COMMENTARY
Background Information
A common approach to learn the func-
tion of a gene is to probe the phenotype of
a cell or organism in which that gene has been
eliminated. For instance, the generation and
characterization of the Yeast Deletion Collec-
tion, a set of yeast strains among which ev-
ery nonessential gene has been knocked out,
has been a powerful tool for investigating gene
function in a simple eukaryote (Giaever & Nis-
low, 2014). Until the development of CRISPR
technology, applying this approach to mam-
malian cells was extremely difficult. Earlier
methods for ablating gene activity included ap-
proaches using zinc-finger nucleases (ZFNs)
and transcription-activator-like effector nucle-
ases (TALENs), both of which contain a DNA
binding domain fused to the FokI nuclease. Al-
though these approaches are capable of gener-
ating a DSB at a specific locus, both ZFNs and
TALENs require complicated re-engineering
of the DNA-binding domains to target differ-
ent DNA sequences. Thus, their versatility and
utility are extremely limited (Gaj, Gersbach, &
Barbas, 2013).
The development of RNA interference
(RNAi) technology in the early 2000s pro-
vided an additional approach for rapid anal-
ysis of gene function in mammalian cells
(Kim & Rossi, 2008). With RNAi, small
interfering RNAs (siRNAs) or short hair-
pin RNAs (shRNAs) could be easily gen-
erated and introduced into mammalian cells
to knock down the expression of a targeted
gene. RNAi technology was harnessed to con-
duct the first whole-genome screens in hu-
man cells, and these methods greatly ad-
vanced the understanding of mammalian biol-
ogy (Kittler & Buchholz, 2005; Kittler et al.,
2004; Mukherji et al., 2006; Nagaoka-Yasuda,
Matsuo, Perkins, Limbaeck-Stokin, & May-
ford, 2007; Whitehurst et al., 2007). How-
ever, experiments conducted with RNAi are
limited in multiple ways. First, RNAi repre-
sents a “partial,” rather than a “total,” loss-
of-function (LOF) perturbation, as RNAi con-
structs decrease protein expression but cannot
fully eliminate the targeted gene. This fea-
ture of RNAi may be especially problematic
when studying enzymes or other proteins that
can tolerate significant changes in gene ex-
pression while still maintaining wild-type lev-
els of activity. Secondly, careful experiments
have revealed that RNAi constructs are highly
prone to off-target knockdowns that can con-
found the characterization of a gene of interest.
Certain results obtained with RNAi have been
called into question after further analysis re-
vealed that the gene ostensibly targeted in an
experiment was not the cause of the resultant
phenotype (Huang et al., 2017; Hu¨bner et al.,
2009; Putzbach et al., 2017). It is important
to note, as discussed below, that CRISPR may
also result in off-target activity, yet these off-
target activity appears to be less promiscuous
than that of RNAi (Boettcher & McManus,
2015). Lastly, RNAi-induced knockdowns are
dependent on the continuous expression of the
RNAi construct. shRNAs transduced into a
cell population can be lost or epigenetically si-
lenced, allowing target re-expression and com-
plicating the use of these cells in long-term
experiments (Ellis, 2005).
The CRISPR system provides several ad-
vantages for perturbing mammalian gene func-
tion compared to either FokI-nuclease- or
RNAi-mediated approaches. Unlike ZFNs and
TALENs, CRISPR is highly versatile, as tar-
geting a new region in a cell line of interest re-
quires only cloning and expressing a 20-bp
oligonucleotide in a guide RNA vector. Un-
like RNAi, CRISPR has the potential to gen-
erate complete loss-of-function perturbations,
bypassing the problems inherent in studying
a partial-LOF phenotype. Head-to-head com-
parisons have also revealed that CRISPR con-
structs exhibit fewer off-target effects than
RNAi constructs (Smith et al., 2017), a dif-
ference that may stem from the more strin-
gent binding and cutting requirements for
Cas9 (Boettcher & McManus, 2015). Finally,
CRISPR has the potential to induce permanent
and stable loss-of-function alterations, allow-
ing long-term analysis of a modified cell line.
CRISPR can be applied to perturb mam-
malian gene function in several ways.
CRISPR-mediated homology-directed repair
can be used to replace a wild-type allele with
a mutation of interest, as has been described
elsewhere (Ran et al., 2013). Alternately, if
the goal of an experiment is simply to elim-
inate gene function, this can be achieved by
targeting Cas9 to that locus and relying on the
cell’s NHEJ pathway to repair the DSB with
indel mutations. A population of cells can be
transfected or transduced with a CRISPR con-
struct at a high multiplicity of infection (MOI),
leading to the development of mutations in a
majority of cells. However, this approach is
likely to generate a heterogeneous cell pop-
ulation: some cells may totally escape tar-
get modification, and certain mutations (e.g.,Giuliano et al.
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in-frame indels) may be tolerated without
compromising protein function. In this pro-
tocol, we instead describe an approach to gen-
erate CRISPR-modified clones derived from
single cells. This strategy allows the construc-
tion of cell lines in which every individual cell
harbors the same set of total LOF (or null)
mutations in a gene of interest.
These CRISPR-knockout cell lines are suit-
able for multiple downstream applications and
can be used to study fundamental questions in
cell biology, genetics, and cancer biology. In
one recent study, for instance, CRISPR was
used to generate isogenic human cell line mod-
els in which different DNA repair genes had
been deleted (Zou et al., 2018). These lines
were allowed to grow in culture for up to
1 month, and the resulting “mutational sig-
natures” caused by each knockout were deter-
mined by whole-genome sequencing. These
patterns of hypermutation were then compared
to the mutational signatures found in human
tumors, allowing the researchers to experi-
mentally verify the genetic underpinnings of
these motifs. In another recent study, CRISPR
was used to identify the transporter that im-
ports the amino acid serine into mitochondria
(Kory et al., 2018). These researchers first per-
formed a CRISPR screen to identify guide
RNAs that cause poor growth specifically in
serine-deficient media. The researchers then
generated cell line knockouts of SFXN1, the
screen’s top hit, and discovered that these lines
were deficient in mitochondrial serine im-
port. These examples illustrate how CRISPR-
induced knockouts allow a precise interroga-
tion of the relationship between genotype and
phenotype, shedding light on the genetic ar-
chitecture of mammalian cells.
CRISPR-generated knockout cell lines are
also useful for investigating the specificity
of drugs, antibodies, and other biological
reagents. For example, a series of exper-
iments using RNAi suggested that multi-
ple cancer types required the expression of
the maternal embryonic leucine zipper ki-
nase (MELK) in order to proliferate (Jiang
& Zhang, 2013). Based on these preclini-
cal results, one company developed a small-
molecule inhibitor of MELK and launched
multiple clinical trials to treat cancer pa-
tients with this compound (Chung et al.,
2012). However, subsequent work from our
lab and the Gray lab at the Dana-Farber In-
stitute demonstrated that cancer cells tolerated
CRISPR-induced mutations in MELK with no
loss in fitness (Giuliano et al., 2018; Huang
et al., 2017; Lin et al., 2017). Thus CRISPR
knockouts can be used to validate findings
obtained using other protein-depletion ap-
proaches. CRISPR knockouts have also been
analyzed to test the specificity of MTH1 in-
hibitors (Kettle et al., 2016), CD95L-targeting
shRNAs (Putzbach et al., 2017), Sema4B-
targeting shRNAs (Peretz et al., 2018), and
an increasing number of antibodies (Thermo
Fisher, 2018; Origene, 2018; Abcam, 2018a).
CRISPR knockouts are therefore a key labora-
tory tool for validating reagents and conduct-
ing reproducible biological research.
Nonetheless, there are multiple potential
pitfalls that can interfere with the generation
and analysis of CRISPR knockout cell lines.
First, some CRISPR-induced mutations can
lead to incomplete target ablation via exon
skipping and/or nonsense-associated alterna-
tive splicing (NAS). In these poorly under-
stood processes, the presence of a nonsense
mutation causes cells to produce an alternative
transcript that bypasses the CRISPR-induced
mutation. Although the resulting transcripts
may differ from the dominant isoform ex-
pressed in a cell line, they may still be suf-
ficient to carry out the function of the protein
(Mou et al., 2017; Rodriguez-Rodriguez et al.,
2018). Secondly, while CRISPR-mediated
mutagenesis can effectively ablate the targeted
locus, the resulting indel can itself have unin-
tended consequences. Long-read sequencing
has recently shown that Cas9-induced DSBs
can cause large deletions and complex rear-
rangements that span multiple kilobases, po-
tentially interfering with the expression or reg-
ulation of nearby genes (Kosicki, Tomberg,
& Bradley, 2018). Finally, challenging a cell
line to repopulate itself from a single progeni-
tor cell represents a significant genetic bottle-
neck and may also select for certain genetic
alterations. For instance, it has been reported
that knocking out genes in a nontransformed
cell line can select for p53 deficiencies, poten-
tially confounding downstream analysis (Haa-
paniemi, Botla, Persson, Schmierer, & Taipale,
2018). It is important to be aware of these po-
tential genetic compensatory mutations, espe-
cially when attempting to knock out an essen-
tial protein.
In this article, we describe a number
of methods that can minimize—but not
eliminate—these potential limitations of
CRISPR-mediated knockout generation. First,
as a means to avoid incomplete protein ab-
lation caused by exon skipping or NAS, we
describe a two-guide system to independently Giuliano et al.
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target two distinct exons. Secondly, we rec-
ommend designing guide RNAs to target con-
served functional domains of the protein of
interest, thereby increasing the likelihood that
a mutation will compromise protein function
(Shi et al., 2015). Thirdly, to address the po-
tential problems caused by evolution and vari-
ability during single-cell clonal expansion, we
suggest the derivation of multiple independent
knockout clones and the use of appropriate
controls during experimental design.
Critical Parameters
The CRISPR/Cas9 system is a powerful
tool for rapidly generating knockout cell lines.
These lines have already proven instrumen-
tal in a number of recent publications by al-
lowing researchers to determine the function
of uncharacterized genes, analyze knockouts
in isogenic backgrounds, and validate the ac-
tivity of small-molecule inhibitors and RNAi
constructs (Giuliano et al., 2018; Huang et al.,
2017; Kory et al., 2018; Lin et al., 2017; Zou
et al., 2018). Nonetheless, there are several
important considerations to take into account
when generating and deploying knockout cell
lines in experimental settings.
First, it is important to consider the ge-
netic, epigenetic, and phenotypic heterogene-
ity that may be present within a population
of cells prior to single-cell isolation. Rederiv-
ing a cell line from a single cell represents
a significant genetic bottleneck, and experi-
ments may be confounded if a single cell–
derived clone captures only a subset of the
diversity present within the starting cell popu-
lation. Indeed, some established cell lines are
well known to exhibit significant interclonal
heterogeneity; for instance, we and others have
observed sizeable variation in proliferative ca-
pacity among clones derived from the widely
used MDA-MB-231 breast cancer cell line
(Giuliano et al., 2018; Khan, Kim, Shin, &
Lee, 2017; Lin et al., 2017). Because of the
possibility of parental heterogeneity, it is ab-
solutely crucial that researchers analyze mul-
tiple independent knockout cell lines in order
to ensure that any unexpected result is not a
clonal artifact.
Secondly, challenging a single cell to prolif-
erate to form a clonal population of millions of
cells represents a significant selective pressure.
This pressure could conceivably enrich for cer-
tain genetic and epigenetic alterations within
the growing clone that promote proliferation.
To account for this selective force, it is impor-
tant to compare experimental knockouts with
clonal “control” cell lines that were derived
under similar conditions. These control cells
should also harbor Cas9 and/or gRNAs target-
ing established nonessential loci to account for
any nonspecific reaction to CRISPR-induced
DNA damage. In our experience, guides tar-
geting confirmed nonessential loci have a
slight but significant effect when compared to
guides that lack any target sites in the genome.
As a result, we recommend against using non-
targeting guide RNAs as experimental con-
trols, and instead suggest that control guide
RNAs be designed to cut at an established safe-
harbor locus in the genome, such as AAVS1 or
Rosa26 (Papapetrou & Schambach, 2016).
As an alternate approach to minimize the
effects of cell cloning, or to verify an unex-
pected result, researchers may consider con-
ducting bulk CRISPR assays in parallel to gen-
erating clonal knockout cell lines. In bulk as-
says, gRNAs can be introduced into the recip-
ient cell line by transfection or transduction,
as described above. If enough cells express
the guide RNA of interest, an assay can be
conducted directly with that population. Oth-
erwise, FACS can be used to isolate a bulk
population of cells harboring that guide, and
that population can be subjected to genetic and
phenotypic analysis. Rescue experiments—in
which cells are generated that express a guide
RNA-resistant allele of the gene of interest—
represent an alternate method to rule out clonal
artifacts and to ensure that a phenotype results
from on-target activity. Importantly, through
the use of CRISPR-mediated HDR, gRNA-
resistance mutations can be introduced di-
rectly into the locus of interest, bypassing
problems that could potentially result from the
transgenic overexpression of resistant cDNA.
In sum, this protocol describes an effec-
tive strategy for generating knockout cell lines
with CRISPR/Cas9. As the CRISPR system
becomes increasingly ubiquitous, CRISPR-
generated knockout cell lines will represent
an essential approach to characterizing gene
function and exploring the activity of biologi-
cal reagents.
Troubleshooting
In this section, we describe common prob-
lems, their likely causes, and appropriate cor-
rective steps.
No plasmids with the correct gRNA
sequence are recovered following cloning
In our experience, the most common cause
of guide RNA cloning problems is incomplete
excision of the BsmBI filler sequence. That
is, ampicillin-resistant colonies are recoveredGiuliano et al.
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following transformation, but sequencing re-
veals that they contain undigested vector with
no gRNA insert. If this occurs, the BsmBI
digestion can be performed overnight to en-
sure complete spacer excision. Alternately, the
use of a new stock of restriction enzyme may
alleviate the problem. Additionally, the re-
searchers should ensure that the agarose gel
has been run long enough to separate the di-
gested fragment from any undigested vector
before performing the gel-extraction step.
If no bacterial colonies are recovered af-
ter transformation, we recommend double-
checking the oligonucleotide sequences to en-
sure that the BsmBI cut-site overhangs have
been added correctly. Additionally, the liga-
tion reaction can be extended from 30 min to
1 hr or longer.
Failure to generate lentivirus
If the lentiviral titer generated is low, sev-
eral steps can be taken to increase virus yield.
First, HEK293T cells that have been left
in culture for too long or under suboptimal
growth conditions may fail to produce suf-
ficient lentivirus. Using freshly thawed low-
passage HEK293T cells can help increase vi-
ral titer. Second, the quality of transfection
reagents can impact lentiviral titer: optimizing
transfection by monitoring the expression of
a GFP-expressing plasmid, in the absence of
lentiviral production, can help identify prob-
lems with transfection reagents. Remaking
these solutions can often eliminate these prob-
lems. Finally, plasmid quality is highly impor-
tant: researchers should ensure that the lentivi-
ral and CRISPR plasmid preparations are pure,
with high concentrations (>500 ng/µl), an
A260/A280 ratio of 1.8, and an A260/A230 ratio
of 2.0.
Cells fail to grow during single-cell
expansion
The plating of single cells can present a
very challenging environment for an individ-
ual cell to grow. If the researchers are agnostic
to cell line identity, they can simply choose to
generate knockout clones in a cell line that ex-
hibits consistently high clonogenicity (HeLa,
HCT116, A375, DLD1, Cal51). Alternately, if
cell line identity is important, there are a num-
ber of modifications that can greatly improve
a cell line’s clonogenic capacity. First, simply
doubling the concentration of serum is suffi-
cient to promote single-cell growth in some
cell lines. If this fails, cell line–conditioned
medium can be used to supplement growth.
To generate conditioned medium, seed 106
cells from the chosen cell line onto a 10-cm
plate. The next day, collect the supernatant,
spin it down, pass it through a 0.45-µm filter,
and then use it to feed the plate on which the
single cells will be deposited.
If each of the above methods have been
tried and no successful knockout clones are
identified, it is possible that the target gene is
essential. We recommend using tools such as
DepMap (https://depmap.org/portal/) to ver-
ify whether your target gene is required in a
particular cell line. If the gene of interest is in-
deed necessary for cell survival, the generation
of knockout clones may not be possible.
The protein of interest cannot be detected by
western
If western blot analysis fails to detect any
protein presence in control samples when
tested with multiple antibodies, it is possible
that the protein of interest is not actually ex-
pressed in the tested cell line. We recommend
consulting the Cancer Cell Line Encyclopedia
or using qRT-PCR prior to single-cell cloning
to ensure that the target gene is expressed in
the cell line of interest (Barretina et al., 2012).
No knockout clones are recovered
If western blot analysis fails to reveal any
apparent knockout clones, this may simply in-
dicate that the antibody used is nonspecific
for its reported target. In this case, we would
suggest that researchers investigate the DNA-
based validation approaches described above.
Redoing the western blots with other antibod-
ies (particularly antibodies that have previ-
ously been knockout-validated) may also iden-
tify true knockout clones.
If DNA-based validation indicates that the
guide RNA cut site lacks any detectable mu-
tations, this may indicate that the cell line
did not express sufficient levels of Cas9 ex-
pression or that the guide RNA was not ac-
tive. If this experiment was done in a stable,
Cas9-expressing cell line, then the researchers
should test Cas9 expression (via qPCR or
western blot) or confirm its activity using a val-
idated guide RNA. Testing alternative guide
RNAs may also allow successful knockout
generation.
Finally, if multiple guide RNAs are tested
and no knockout clones can be derived, it
may be the case that the targeted gene is
essential for cell survival and thus knockout
generation is not possible. The derivation of
many heterozygous clones may indicate that
the CRISPR system is working effectively, but Giuliano et al.
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complete knockout of the gene of interest is
lethal.
Knockout clones lack any detectable
phenotype or display an unexpected
phenotype
Single cell–derived clones can exhibit sig-
nificant clonal variability, particularly in ge-
nomically unstable cell lines. It is always best
to generate and analyze multiple knockout
clones, if possible using different guide RNA
combinations. In order to confirm that an unex-
pected phenotype is a true consequence of the
loss of the targeted gene, rescue experiments
can be performed by expressing guide RNA–
resistant cDNAs in each clone. If no identi-
fiable phenotype is detected, the researchers
may wish to investigate the effects of ablat-
ing gene function without single-cell cloning
(for instance, by transducing high-titer gRNA
lentivirus and analyzing the population that
results). Alternately, it is possible that the tar-
geted gene is truly dispensable for the expected
phenotype in the cell line being tested.
Understanding Results
Verified knockout clones should demon-
strate gene knockout according to both gene
evidence by PCR and Sanger sequencing and
protein evidence by western blotting, as shown
in Figures 2 and 3.
Western blot analysis remains the gold
standard for verifying protein knockout.
If an antibody detects the expression of a
protein in a wild-type or control clone but
fails to detect the expression of that same
protein in a putative knockout clone, that
is strong evidence that the targeted protein
has been ablated. However, a number of
factors may confound this analysis. First,
a CRISPR-induced lesion may ablate the
antigen specifically recognized by an antibody
without eliminating all protein expression.
This could lead to a false-positive result, in
which a western blot seemingly confirms the
absence of a target although it remains present
in the cell line. Secondly, alternative splicing
or downstream translational initiation could
lead to the production of functional protein
fragments. These smaller isoforms may be
dismissed as degradation products on a west-
ern blot or may not be detected if the blot is
cut based on the expected size of the wild-type
gene product. Thirdly, many commercially
available antibodies are nonspecific for their
reported targets, potentially confounding
western blot analysis (Berglund et al., 2008;
Voskuil, 2014). Many of these problems can
be overcome by targeting genes with multiple
independent guide RNAs and validating
knockouts with more than one antibody. For
instance, by assessing protein expression with
antibodies raised against different antigens
present within the target, one can effectively
rule out the possibility that the gene still
produces functional protein fragments. It may
require testing three to six antibodies to iden-
tify two to three that are suitable for western
blotting, specific for the targeted protein,
and that recognize unique antigens. These
concerns aside, standard western blotting pro-
tocols, as published elsewhere, are generally
sufficient for this analysis (Abcam, 2018b;
JoVE Science Education Database, 2018; Cur-
rent Protocols article: Gallagher et al., 2008).
If a cell line is transfected or transduced
with two independent guide RNAs that target
the same gene, recombination between these
lesions will occasionally cause the deletion of
the intervening genomic DNA. The frequency
of this event will vary based on the distance
between the cut sites, the local chromatin con-
text, the identity of the specific cell line, and
several other factors. Nonetheless, using two
guides to eliminate multiple exons in a tar-
geted gene is a good strategy to ensure com-
plete target ablation. At the same time, these
large deletions may be more likely to affect
the expression of nearby genes and could also
eliminate intronic microRNAs, transcription-
factor binding sites, or other important regula-
tory elements. As we describe, recombination
between two distant cut sites can be easily
detected by PCR using one primer that is up-
stream of the 5′ cut site and another primer
that is downstream of the 3′ cut site. A sec-
ond set of primers that recognize sequences
between the cut sites can be used to differ-
entiate between clones that are homozygous
and heterozygous for the deletion event. This
approach can be easily applied to screen a
large number of clones and represents a reli-
able, antibody-independent approach to iden-
tify knockouts.
Time Considerations
Generating the cloned plasmids will take
2 days, followed by another 2 to 3 days to
verify the insert by sequencing. Time consid-
erations for the introduction of the CRISPR
system to the cell line of interest depend
on the methodology chosen: 2 days are re-
quired to generate any lentivirus; generation
of stable Cas9 expressing cell line may take
1 to 2 weeks depending on selection effi-
ciency; transduction or transfection of a gRNAGiuliano et al.
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vector to a recipient cell line will take 2 to 3
days. Expansion of single-cell clones is often
the lengthiest part of the process, with single-
cell expansion rates ranging from 3 to 6 weeks
depending on the proliferation rate of the cell
line. Subsequent knockout validation assays
(western blotting, PCR, Sanger sequencing)
all take 1 to 3 days, assuming that the reagents
have previously been optimized.
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